- Frencken's 3Q22 earnings of S$11m (-26% y-o-y/-17% q-o-q) was below expectations, 9M22 formed 66% of our full-year estimate. 3Q22 revenue fell 1% y-o-y, with semiconductor (+16% y-o-y), life science (+8% y-o-y) and medical (+3% y-o-y) recording growth while industrial automation (-35% y-o-y) and automotive (-7% y-o-y) declined.
- - Read this at SGinvestors.io -
- We cut our 2022 and 2023 EPS forecast for Frencken by 16%. Downgrade Frencken to HOLD.
Flattish revenue in 3Q22 with mixed performance across different segments.
- - Read this at SGinvestors.io -
- 3Q22 revenue of S$195m (-0.6% y-o-y/+2.5% q-o-q) was led by growth from the semiconductor (+16% y-o-y), life science (+8% y-o-y) and medical (+3% y-o-y) sectors.
- Growth in the semiconductor space was lifted by higher orders for front-end semiconductor equipment from customers in Europe and Asia. However, sales in the industrial automation (-35% y-o-y) and automotive (-7% y-o-y) sectors were impacted by reduced customer demand and bottlenecks in the global supply chain.
Cost pressures expected to ease in 2H22.
- Read more at SGinvestors.io.
